BioCryst Pharmaceuticals | BCRX - Stock


BioCryst Pharmaceuticals reported $5.98M in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
Alnylam Pharmaceuticals USD 200.15M 117.43M Mar/2026
BioCryst Pharmaceuticals USD 5.98M 587K Mar/2026
Chugai Pharma JPY 276.85B 30.52B Dec/2025
Daiichi Sankyo JPY 608.55B 93.64B Sep/2025
Gilead Sciences USD 1.91B 140M Mar/2026
GlaxoSmithKline GBP 6.16B 233M Mar/2026
Glaxosmithkline GBP 6.12B 46M Sep/2025
Incyte USD 115.62M 14.56M Mar/2026
Ionis Pharmaceuticals USD 5.56M 4.49M Mar/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
Novavax USD 11.46M 87K Mar/2026
PTC Therapeutics USD 75.57M 4.08M Mar/2026
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sarepta Therapeutics USD 1B 86.37M Mar/2026
Ultragenyx Pharmaceutical USD 55M 3M Mar/2026
Vertex Pharmaceuticals USD 1.77B 79.9M Mar/2026